Literature DB >> 33728245

Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III.

Sarah P Young1,2, Aleena Khan1, Ela Stefanescu1, Andrea M Seifts2, Ghada Hijazi1, Stephanie Austin1, Priya S Kishnani1.   

Abstract

AIM: The urinary glucose tetrasaccharide, Glcα1-6Glcα1-4Glcα1-4Glc (Glc4), is a glycogen limit dextrin that is elevated in patients with glycogen storage disease (GSD) type III. We evaluated the potential of uncooked cornstarch therapy to interfere with Glc4 monitoring, by measuring the diurnal variability of Glc4 excretion in patients with GSD III.
METHODS: Voids were collected at home over 24 hours, stored at 4°C and frozen within 48 hours. Glc4 was analyzed using liquid chromatography-tandem mass spectrometry and normalized to creatinine.
RESULTS: Subjects with GSD III (median age: 13.5 years, range: 3.7-62; n = 18) completed one or more 24-hour urine collection, and 28/36 collections were accepted for analysis. Glc4 was elevated in 16/18 subjects (median: 13 mmol/mol creatinine, range: 2-75, reference range: <3). In collections with elevated Glc4 (23/28), two-thirds (15/23) had low diurnal variability in Glc4 excretion (coefficient of variation [CV%] <25). The diurnal variability was significantly correlated with the Glc4 concentration (Pearson R = .644, P < .05), but not with the dose of uncooked cornstarch. High intraday variability (>25%) was not consistently observed in repeat collections by the same subject.
CONCLUSIONS: The extent and variability of Glc4 excretion relative to creatinine was not correlated with cornstarch dose. A majority of collections showed low variability over 24 hours. These findings support the use of single time-point collections to evaluate Glc4 in patients with GSD III treated with cornstarch. However, repeat sampling over short time-periods will provide the most accurate assessment of Glc4 excretion, as intraday variability may be increased in patients with high Glc4 excretion.
© 2020 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.

Entities:  

Keywords:  24‐hour urine; Glc4; Hex4; biomarker; glucose tetrasaccharide; glycogen storage disease type III; uncooked cornstarch

Year:  2020        PMID: 33728245      PMCID: PMC7932871          DOI: 10.1002/jmd2.12181

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  31 in total

1.  Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.

Authors:  Sarah P Young; Monique Piraud; Jennifer L Goldstein; Haoyue Zhang; Catherine Rehder; Pascal Laforet; Priya S Kishnani; David S Millington; Mustafa R Bashir; Deeksha S Bali
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

2.  Nesiritide as bridge to multi-organ transplantation: a case report.

Authors:  A B Cochrane; S E Fedson; D C Cronin
Journal:  Transplant Proc       Date:  2007 Jan-Feb       Impact factor: 1.066

3.  Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen.

Authors:  J Kumlien; M A Chester; B S Lindberg; P Pizzo; D Zopf; A Lundblad
Journal:  Clin Chim Acta       Date:  1988-08-15       Impact factor: 3.786

4.  The subgroups of type 3 glycogenosis.

Authors:  F Van Hoof; H G Hers
Journal:  Eur J Biochem       Date:  1967-10

5.  Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease.

Authors:  Y An; S P Young; S L Hillman; J L Van Hove; Y T Chen; D S Millington
Journal:  Anal Biochem       Date:  2000-12-01       Impact factor: 3.365

6.  Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry.

Authors:  G Lennartson; A Lundblad; S Sjöblad; S Svensson; P A Ockerman
Journal:  Biomed Mass Spectrom       Date:  1976-04

7.  Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring.

Authors:  Carine A Halaby; Sarah P Young; Stephanie Austin; Ela Stefanescu; Deeksha Bali; Lani K Clinton; Brian Smith; Surekha Pendyal; Jariya Upadia; Gary R Schooler; Alisha M Mavis; Priya S Kishnani
Journal:  Genet Med       Date:  2019-07-02       Impact factor: 8.822

8.  Glycogen storage disease type III: modified Atkins diet improves myopathy.

Authors:  Sebene Mayorandan; Uta Meyer; Hans Hartmann; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-11-28       Impact factor: 4.123

9.  Spot urine estimations are equivalent to 24-hour urine assessments of urine protein excretion for predicting clinical outcomes.

Authors:  Boon Wee Teo; Ping Tyug Loh; Weng Kin Wong; Peh Joo Ho; Kwok Pui Choi; Qi Chun Toh; Hui Xu; Sharon Saw; Titus Lau; Sunil Sethi; Evan J C Lee
Journal:  Int J Nephrol       Date:  2015-01-08

10.  Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort.

Authors:  Monique Piraud; Magali Pettazzoni; Marie de Antonio; Christine Vianey-Saban; Roseline Froissart; Brigitte Chabrol; Sarah Young; Pascal Laforêt
Journal:  Mol Genet Metab Rep       Date:  2020-05-01
View more
  2 in total

Review 1.  Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa: A clinical study and review of the literature.

Authors:  Anna Paschall; Aleena A Khan; Syed Faaiz Enam; Tracy Boggs; Ghada Hijazi; Michael Bowling; Stephanie Austin; Laura E Case; Priya Kishnani
Journal:  Mol Genet Metab       Date:  2021-10-09       Impact factor: 4.797

2.  A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.

Authors:  Ghada Hijazi; Anna Paschall; Sarah P Young; Brian Smith; Laura E Case; Tracy Boggs; Sathya Amarasekara; Stephanie L Austin; Surekha Pendyal; Areeg El-Gharbawy; Kristen L Deak; Andrew J Muir; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2021-11-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.